Pacific Biosciences of California Inc
Change company Symbol lookup
Select an option...
PACB Pacific Biosciences of California Inc
OPCH Option Care Health Inc
OLFC Olfactory Biosciences Corp
OJSCY NK Rosneft' PAO
OCRNL NK Rosneft' PAO
OARFF Fort St James Nickel Corp
MDXG MiMedx Group Inc
CATY Cathay General Bancorp
EADSF Airbus SE
ARAY Accuray Inc
Go

Health Care : Life Sciences Tools & Services | Small Cap Blend
Company profile

Pacific Biosciences of California, Inc. designs, develops and manufactures sequencing systems to help scientists resolve genetically complex problems. The Company is engaged in the development, manufacturing and marketing of an integrated platform for genetic analysis. Its Single Molecule, Real-Time (SMRT) technology enables single molecule, real-time detection of biological processes. It offers The SMRT Cell, Phospholinked nucleotides and The PacBio RS II and Sequel instruments. Its SMRT technology enables the observation of deoxyribonucleic acid (DNA) synthesis as it occurs in real-time by harnessing the natural process of DNA replication, which is actuated by the DNA polymerase. Its phospholinked nucleotides have a fluorescent dye attached to the phosphate chain of the nucleotide rather than to the base. The PacBio RS II and Sequel instruments include optics, automated liquid handling, a touchscreen control interface and computational hardware and software.

Closing Price
$9.25
Day's Change
0.34 (3.82%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.26
Day's Low
8.73
Volume
(Average)
Volume:
4,131,897

10-day average volume:
4,477,068
4,131,897

Sonnet BioTherapeutics to Present at the 2020 BTIG Virtual Biotechnology Conference

7:30 am ET July 15, 2020 (Accesswire) Print

PRINCETON, NJ / ACCESSWIRE / July 15, 2020 / Sonnet BioTherapeutics, Inc., a company developing innovative targeted biologic drugs with enhanced single or bispecific mechanisms, announced today that Pankaj Mohan, PhD, Founder and Chief Executive Officer, John Cini, PhD, Co-founder and Chief Scientific Officer and Jay Cross, Chief Financial Officer, will be presenting a corporate overview at the BTIG Virtual Biotechnology Conference, held August 10-11, 2020.

Sonnet BioTherapeutics Fireside Chat Details:

2020 BTIG Virtual Biotechnology ConferenceDate: Monday, August 10, 2020Presentation Time: 3:30 PM ET

About Sonnet BioTherapeutics, Inc.

Founded in 2011, Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for innovating biologic drugs of single or bispecific action. Known as FHAB (Fully Human Albumin Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitchhikes" on human serum albumin (HSA) for transport to target tissues. FHAB is the foundation of a modular, plug-and-play construct for potentiating a range of large molecule therapeutic classes, including cytokines, peptides, antibodies and vaccines.

Sonnet Biotherapeutics Investor Contact

Alan LadaSolebury Trout617-221-8006alada@soleburytrout.com

SOURCE: Sonnet BioTherapeutics, Inc.

View source version on accesswire.com: https://www.accesswire.com/597464/Sonnet-BioTherapeutics-to-Present-at-the-2020-BTIG-Virtual-Biotechnology-Conference

comtex tracking

COMTEX_368078463/2457/2020-07-15T07:30:09

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.